Articles On Imugene (ASX:IMU)

Finally, a positive day for the S&P/ASX 200 Index (ASX: XJO)! After falling in both Monday and Tuesday’s sessions, this week was turning out to be a rather depressing one. Thankfully, the ASX 200 turned a corner this Wednesday and d...

The Energy sector demonstrated strong growth, with a rally of 1.7%. Ampol (ASX:ALD) experienced a significant surge of 4.4% following robust fuel sale volumes reported for the first half of the financial year 2023. Woodside Petroleum (ASX:W...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage immuno-oncology company Imugene (ASX: IMU) has received a notice of allowance from the US Patent and Trademark Office for a patent to protects its prima...

Imugene (IMU) receives US patent approval to protect its oncolytic virotherapy CF33, including VAXINIA and CHECKVacc The patent, “Chimeric Poxvirus Composition and Uses Thereof”, protects the company’s method of composition and treatment...

Woodside Energy (ASX:WPL), reported a 29% decline in revenue for the second quarter, amounting to $US3.1 billion (A$4.5 billion). Sales of oil decreased by 4%, with 48.4 million barrels sold, while production experienced a 5% drop to 44.5 m...

Highlights Imugene has secured a patent for its licenced oncolytic virotherapy in the United States. Oncolytic virotherapy CF33 comprises CHECKVacc and VAXINIA. The patent protects the composition and usage methodology of the oncolyti...

The Peninsula Energy Ltd (ASX: PEN) share price is having a day to forget on Wednesday. At one stage today, the ASX All Ordinaries share was down as much as 30% to 12.5 cents. It has since bounced back a touch but remains down 22% at 14 ce...

The Imugene Ltd (ASX: IMU) share price is leaping higher today, up 7.5% at the time of writing. Shares in the S&P/ASX 200 Index (ASX: XJO) biotechnology company closed yesterday trading for 9.3 cents. Shares are currently swapping hand...

  ImpediMed (ASX:IPD) are the first top 5 national payor covering SOZO testing for cancer patients at risk for lymphoedema. In response, CEO and MD Richard Valencia said, ”Cigna’s policy provides access to coverage for all individuals at ri...

The BetaShares Australian Dividend Harvester Fund (ASX: HVST) is one of the more popular high-yield ASX exchange-traded funds (ETFs) that investors can buy to aim for high dividend yields. Some ETFs can be focused on holding businesses for...

Highlights Imugene has appointed Dr Ron Weitzman as its interim CMO. Dr Weitzman has an experience of over 20 years in the biopharmaceutical space. Dr Weitzman has extensive record in clinical development plan development and executio...

19 Jul 2023 - A snapshot of the stocks on the move, featuring ImpediMed (ASX:IPD), Imugene Limited (ASX:IMU) and Brightstar Resources (ASX:BTR).

Tim Boreham highlights the potential for cancer treatment biotech Arovella Therapeutics. By Tim Boreham ASX code: ((ALA)) Share price: 4.8 cents Shares on issue: 899,149,698 Market cap: $44 million Chief executive officer: Dr Michael Baker...

The fund manager L1 Capital has identified two S&P/ASX 200 Index (ASX: XJO) shares that could be great value opportunities to invest in. L1 is still cautious on the outlook for the stock market “given the looming impact of significan...

The ASX 200 is down nearly 0.5 per cent at market close, declining throughout the day after a strong start.  Information Technology was the only sector to hold up in the green, with Vista Group, Echo IQ, Bigtincan Holdings, Orcoda, ArchT...

This content is created by Smallcaps Authors. [Author : Colin Hay] Clinical stage immuno-oncology company Imugene (ASX: IMU) has confirmed that the world-renowned City of Hope independent cancer research and treatment centre will lead a t...

Imugene (IMU) to proceed with a fourth dose cohort in the phase one trial of its oncolytic virotherapy candidate, CHECKvacc Independent cancer research centre City of Hope reported no toxic effects to date IMU CEO Leslie Chong says th...

Highlights Phase I clinical trial of CHECKvacc is set to proceed to the fourth dose cohort. The trial of the oncolytic virotherapy candidate is designed to treat patients with triple negative breast cancer (TNBC). The study focuses on...

The Vulcan Energy Resources Ltd (ASX: VUL) share price is pushing higher again on Tuesday. In afternoon trade, the lithium developer’s shares are up 6% to $4.55. This means the company’s shares are now up 20% since this time last week....

It’s been a bumpy but overall positive end for the S&P/ASX 200 Index (ASX: XJO) for this Friday, this week and for the 2023 financial year. The ASX 200 has finished up in the green today, recording a gain of 0.12%. That puts the ind...

ASX value shares and growth shares both went up in FY23, but value stocks did a bit better. The S&P/ASX 200 Value Index is up 8.32% in the financial year to date. If you take dividends into account, the total return for FY23 is 13.55%...

It’s the last day of the financial year and significant changes are set to take place from tomorrow. Australia’s minimum wage will increase to just above $23 per hour. Superannuation figures will also increase from 10.5 per cent to 11 p...

The S&P/ASX 200 Index (ASX: XJO) is on course to finish the week with a small decline. At the time of writing, the benchmark index is down slightly to 7,192.5 points. Four ASX shares that are not letting that hold them back today are...

Highlights Imugene’s new and significant HER-Vaxx data has been presented at the World Congress of Gastrointestinal Cancer in Barcelona. The abstract presented was about ‘HERIZON: A Phase 2 study of HER-Vaxx (IMU-131)’. The World Con...

Imugene (IMU) presents “new and significant” HER-Vaxx data at the World Congress of Gastrointestinal Cancer in Barcelona The company reported its HER-Vaxx-induced antibodies correlated with tumour reduction in patients with advanced stom...

ASX set to open lower this morning after a slow day on Wall Street overnight. ASX 200 Futures Index was in a fickle mood all morning, hovering around zero change. Health tech Immugene has some huge news from a major conference in Barcelona...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage immuno-oncology company Imugene (ASX: IMU) has introduced “new and significant data” relating to lead candidate HER-Vaxx to delegates at the World Congr...

There were 432,000 job vacancies in May 2023 – 9,000 less than in February. The Australian Bureau of Statistics this morning revealed the two per cent drop, marking the fourth consecutive quarterly fall in available jobs. However, whi...

Imugene (IMU) receives an extension of its PD1-Vaxx patent from the United States Patent Office until 2040 The patent titled, “HUMAN PD1 Peptide Vaccines And Uses Thereof”, includes 685 days of patent term adjustments to its original exp...

Highlights The United States Patent Office has awarded a patent to the company’s immunotherapeutic PD1-Vaxx. The vaccine is being designed for patients with non-small cell lung cancer (NSCLC). The patent will expire in 2040. Clini...

This content is created by Smallcaps Authors. [Author : Imelda Cotton] Clinical stage immuno-oncology company Imugene (ASX: IMU) has been granted a patent extension by the US Patent Office to protect its immunotherapeutic PD1-Vaxx for the...

What a day for the S&P/ASX 200 Index (ASX: XJO) we had this Wednesday. After yesterday’s more tentative recovery, investors have stepped on the gas in terms of buying pressure. By the end of today’s session, the ASX 200 had risen by a...

The ASX jumps 1.1pc on better-than-expected inflation figures. Australia’s rate of inflation pulled back to 5.6 per cent for the 12 months to May, down from 6.8 per cent the previous month. This reduces pressure on the Reserve Bank to...

The All Ordinaries Index (ASX: XAO) is up a healthy 1.09% in afternoon trade, boosted by today’s unexpectedly muted inflation print. And these three ASX All Ordinaries stocks are doing more than their share of the lifting. Here’s why...

The Nickel Industries Ltd (ASX: NIC) share price is pushing higher on Wednesday morning. At the time of writing, the ASX 200 mining share is up 1.5% to 88.2 cents. However, this doesn’t change much on a year-to-date basis. The Nickel Ind...

Wilsons equity strategist Rob Crookston is a happy man. Despite the turbulence in the general market, many of his team’s S&P/ASX 200 Index (ASX: XJO) holdings in the focus portfolio enjoyed earnings upgrades in recent times. Like a pro...

The Imugene Limited (ASX: IMU) share price has continued downward in the last 12 months, with the clinical-stage immuno-oncology company declining further in 2023. Unlike the reasonable 3.5% return of the S&P/ASX All Ordinaries Index...

Argosy Minerals Limited (ASX: AGY) shares have been having a tough time in 2023. Since the start of the year, the lithium developer’s shares have lost approximately a third of their value. As a comparison, Core Lithium Ltd (ASX: CXO) sha...

Highlights IMU has welcomed Ms Kim Drapkin, a prominent US biotech executive, as Non-Executive Director. Ms Drapkin has an experience of over 25 years in the pharmaceutical and biotechnology space. She has extensive knowledge of the U...

The S&P/ASX 200 Index (ASX: XJO) is on course to end the week with a strong gain. At the time of writing, the benchmark index is up 1% to 7,247.5 points. Four ASX shares that have failed to follow the market higher today are listed be...

There were some defining moments for scores of ASX shares over the week gone by. Here are five stocks that made it to the top of my list. ASX shares that boomed during the week Nickel Industries Ltd (ASX: NIC) closed out the week with a ba...

The S&P/ASX 200 Index (ASX: XJO) traded in the green on Friday, closing the week 0.32% higher at 7,122.5 points. That sees it 0.32% lower week-on-week. Today’s gains came on the back of a strong session on Wall Street overnight. The...

Imugene says it is ready to advance to the phase of testing for its cancer-killing virus, the VAXINA MAST, having cleared patient cohorts one, two, and three, and readies itself to kickstart cohort four. The post Imugene’s [ASX:IMU] Shares...

The market is tracking higher in midday trade, up nearly 0.5 per cent. Economists from the Commonwealth Bank of Australia (CAB) have forecast the chances of Australia going into recession this year are sitting at 50 per cent. Seven o...

It’s looking like the S&P/ASX 200 Index (ASX: XJO) is heading for a positive end to the trading week, and an especially welcome start to the long weekend. At the time of writing, the ASX 200 has smoothly risen by a healthy 0.37%, putti...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positive note. At the time of writing, the benchmark index is up 0.4% to 7,126.8 points. Four ASX shares that are climbing more than most today ar...

It’s a bright day on the bourse, with the All Ordinaries Index (ASX: XAO) lifting 0.37% at the time of writing. And its moves have been helped and hindered by three All Ords stocks posting some significant gains and falls. The trio are o...

Imugene’s (IMU) phase one metastatic advanced solid tumours (MAST) trial evaluating its novel cancer-killing drug, VAXINIA, progresses to its fourth cohort Meanwhile, cohort one of IMU’s combination study using Pembrolizumab is cleared...

Anteris’ study is progressing well at the one year and 30-day time points Imugene’s Phase 1 trial has progressed to the next cohort level Nyrada has a new lead drug   Regenerative medicine biotech Anteris Technologies (ASX:AVR) has just p...

This content is created by Smallcaps Authors. [Author : Colin Hay] Advanced immuno-oncology specialist Imugene (ASX: IMU) is preparing for the next phase of testing of a novel cancer-killing virus. The company is preparing to test a new c...